ANNX Form 4 shows director’s multi-day common stock purchases
Rhea-AI Filing Summary
Annexon, Inc. (ANNX) director reports sizable insider stock purchases. Over three consecutive days in November 2025, the reporting person, through Alerce Medical Technology Partners, L.P., bought 500,000 Annexon common shares on each of 11/17, 11/18, and 11/19.
The weighted average purchase prices were reported as $2.99, $3.18, and $3.94 for each respective day, with trades executed within stated price ranges. After these transactions, the reporting person beneficially owned 8,906,024 shares indirectly, including shares held in a revocable trust, various other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, subject to stated pecuniary interests.
Positive
- None.
Negative
- None.
Insights
Director, through affiliated funds and trusts, increased indirect ownership by 1.5M Annexon shares via open-market purchases over three consecutive days.
The filing shows a board member, acting through **Alerce Medical Technology Partners, L.P.**, buying **500,000** shares of **common stock** on each of
The ownership structure is spread across a revocable trust, other trusts and entities, **Satter Medical Technology Partners, L.P.**, and **Alerce Medical**, with the reporting person having sole voting and dispositive power over all such shares. The person formally disclaims beneficial ownership of many of these shares beyond their economic interest, which is typical when acting as trustee or manager. The key practical point is a sizable incremental open-market purchase by an existing director-affiliated holder, which increases the aggregate stake linked to this individual over a short period.
Items to monitor include any future Form 4 filings indicating whether this buying continues or reverses, as well as any parallel changes in filing status if ownership levels or roles shift. The execution ranges disclosed for each day’s trades may also matter for anyone analyzing trading liquidity around
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 500,000 | $3.94 | $1.97M |
| Purchase | Common Stock | 500,000 | $3.18 | $1.59M |
| Purchase | Common Stock | 500,000 | $2.99 | $1.50M |
Footnotes (1)
- All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. This transaction was executed in multiple trades in prices ranging from $2.695 to $3.115, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. As of November 19, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 6,951,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein. This transaction was executed in multiple trades in prices ranging from $3.01 to $3.285, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $3.57 to $4.19, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
